The Pharmacological Management of Stress Reactions

  • Jason M. Noel
  • Judy L. Curtis


The use of drug therapies in the management of acute stress reactions and chronic stress-related disorders has emerged as understanding of the pathophysiology of these conditions has become better understood. The general approach to treatment has evolved from the use of predominantly rapid-acting sedative agents for the treatment of acute anxiety attacks, to the more frequent use of agents to control the underlying anxiety disorder.


Anxiety Disorder Generalize Anxiety Disorder Sexual Dysfunction Social Phobia Social Anxiety Disorder 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. American Psychiatric Association. (2004). Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. Arlington, VA: American Psychiatric Association. Available online at: Scholar
  2. American Psychiatric Association. (2009). Treatment of patients with panic disorder. Arlington, VA: American Psychiatric Association. Available online at: Scholar
  3. Brown, C., Rakel, R., Wells, B., Downs, J., & Akiskal, H. (1993). A practical update on anxiety disorders and their pharmacologic treatment. Archives of Internal Medicine, 151, 873–884.CrossRefGoogle Scholar
  4. Duman, R. S., Malberg, J., & Thome, J. (1999). Neural plasticity to stress and antidepressant treatment. Biological Psychiatry, 46, 1181–1191.PubMedCrossRefGoogle Scholar
  5. Grimsley, S. R. (1995). Anxietydisorders. In L. Y. Young, M. A. Koda-Kimble, W. A. Kradjan, & B. J. Guglielmo (Eds.), Applied therapeutics: The clinical use of drugs (6th ed., pp. 73-1–73-31). Vancouver, WA: Applied Therapeutics.Google Scholar
  6. Hamilton, H., Gallagher, P., Ryan, C., Byrne, S., & O’Mahony, D. (2011). Potentially Inappropriate Medications Defined by STOPP Criteria and the Risk of Adverse Drug Events in Older Hospitalized Patients. Archives of Internal Medicine, 171, 1013–1019.PubMedCrossRefGoogle Scholar
  7. Hellweg, R., Ziegenhorn, A., Heuser, I., & Deuschle, M. (2008). Serum concentrations of nerve growth factor and brain-derived neurotrophic factor in depressed patients before and after antidepressant treatment. Pharmacopsychiatry, 41(2), 66–71.PubMedCrossRefGoogle Scholar
  8. Kent, J. M., Coplan, J. D., & Gorman, J. M. (1998). Clinical utility of the selective serotonin reuptake inhibitors in the spectrum of anxiety. Biological Psychiatry, 44, 812–824.PubMedCrossRefGoogle Scholar
  9. Lorenz, R., Jackson, C. W., & Saitz, M. (2010). Adjunctive use of atypical antipsychotics for treatment-resistant generalized anxiety disorder. Pharmacotherapy, 30(9), 942–951.PubMedCrossRefGoogle Scholar
  10. Schweizer, E., Rickels, K., & Lucky, I. (1986). Resistance to the anti-anxiety effect of buspirone in patients with a history of benzodiazepine use. New England Journal of Medicine, 314, 719–720.Google Scholar
  11. Spiegel, D. A., Wiegel, M., Baker, S. L., & Greene, K. A. I. (2000). Pharmacological management of anxiety disorders. In D. I. Mostofsky & D. H. Barlow (Eds.), The management of stress and anxiety in medical disorders (pp. 36–65). Needham Heights, MA: Allyn & Bacon.Google Scholar
  12. Stahl, S. M. (2000). Essential psychopharmacotogy (2nd ed.). New York: Cambridge University Press.Google Scholar
  13. The American Geriatrics Society. (2012) Beers Criteria Update Expert Panel. American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. Journal of the American Geriatrics Society Available online at:

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Jason M. Noel
    • 1
  • Judy L. Curtis
    • 2
  1. 1.University of Maryland School of PharmacyBaltimoreUSA
  2. 2.Sunovion PharmaceuticalsBaltimoreUSA

Personalised recommendations